This week in Clipboard Health’s Nursing News round-up …
Fauci Warns COVID-19 Statistics Indicate Disturbing Reality
Dr. Anthony Fauci cited statistics showing that the U.S. will enter the flu season with an average of 40,000 new cases and 1,000 deaths per day. Fauci, disagreeing with President Trump’s statement that the U.S. had “turned a corner” with the pandemic, said that any return to pre-COVID-19 normalcy won’t happen until possibly the end of 2021.
New Executive Order to Control Drug Prices Signed by Trump
A new executive order signed on Sunday by President Donald Trump expanded on a July executive order to control United States drug prices. Put simply, the order will match the price for medications to the lowest price paid in other countries, but experts and leading pharmaceutical companies say the issue is much more complex and controversial than that.
Actual implementation of both the July and September executive order is delayed until new regulations addressing the issue can be made and put into place.
WHO Encourages Countries to Rethink Elderly Care
Nursing home COVID-19 fatalities have been incredibly high from the pandemic, overwhelming many centers that were ill-equipped to handle the outbreaks. The World Health Organization on Monday called for countries to rethink how we care for the elderly and to view their care as a rights issue.
The WHO also encouraged countries to reevaluate and address unequal health care access and improve protections for at-risk groups like prisoners, migrants, and health care workers.
International Pandemic Monitoring Board Criticizes COVID-19 Failure of World Leaders
The Global Preparedness Monitoring Board (GPMB) released its yearly report, “A World in Disorder,” in which it highlighted the failure of world leaders to properly prepare for the COVID-19 pandemic despite multiple warnings. This board is made up of the world’s leading disease experts to track and advise worldwide readiness for disease outbreaks.
The GPMB’s 2019 report, titled “A World at Risk” and issued a few months before the COVID-19 pandemic began, warned that the world was at risk for a pandemic and encouraged world leaders to prepare accordingly by investing in pandemic preparedness and health care systems.
UK Trials Monoclonal Antibody Treatment for COVID-19 Patients
Monoclonal antibodies have been used for several decades to treat various illnesses, and now their efficacy will be tested in treating COVID-19 patients. The UK Recovery Trial, the group that found dexamethasone could be used to successfully treat hospitalized COVID-19 patients, will begin testing the antibody treatment in the UK in the next few weeks.
Study Finds Adults Who Eat at Restaurants Twice as Likely to Get COVID-19
A new study published by the U.S. Centers for Disease Control and Prevention found that adults with positive COVID-19 tests were twice as likely to have eaten out at restaurants in the two weeks before getting the positive test.
Medical Studies Round-up
Here’s a brief roundup of recent medical studies and their findings for you to stay up-to-date with the ever-evolving field of medical research.
- Researchers from University Hospitals Cleveland Medical Center, OH, found that areas with high levels of poverty and social deprivation have higher mortality rates from heart failure.
- European researchers find a link between Vitamin D in the blood and predicting the likelihood of future health risks in older men.
- Sweden-based researchers identify insomnia has a new risk factor for type 2 diabetes.
- Researchers from the University of Navarra in Spain found that consuming ultra-processed foods shortens telomeres, which are markers used to determine biological aging.
- Researchers at the University of Colorado in Denver find that asthma may not be a high-risk pre-existing condition for severe COVID-19 outcomes.
- Infectious COVID-19 can exist in the gastrointestinal tract almost a week after negative nasopharyngeal swab tests.
Race for the Vaccine: Coronavirus Vaccine Updates
One top vaccine trial had a temporary pause while others continue with the earliest estimated to have results by October. Another country grants emergency approval for use of a vaccine.
AstraZeneca, one of the leaders in the COVID-19 vaccine race, voluntarily paused their Phase III clinical trials for several days. The pause came when a single participant had an unexplained illness that triggered an independent safety review. The clinical trials were cleared to continue on Monday.
Russia reported that it has successfully finished recruiting 55,000 volunteers for Phase III testing of its COVID-19 vaccine.
The United Arab Emirates granted emergency approval to use a COVID-19 vaccine for frontline essential workers. The vaccine, developed by Chinese-based company Sinopharm, is currently in the late stages of Phase III clinical trials.
Pfizer and partner BioNTech, another leader in COVID-19 vaccine development, enrolled more than 29,000 volunteers for its Phase III testing. This specific trial aims to enroll 44,000 volunteers. The hope is to have results on the vaccine’s success from the trials as early as October.
The University of Hong Kong received approval to begin Phase I of clinical trials for its nasal spray COVID-19 vaccine.
Sanofi and GSK begin Phase I and II clinical trials on its COVID-19 vaccine, which is based on Sanofi’s flu vaccines.
Why Are There So Many COVID-19 Vaccines in Development?
There are many ways to make a vaccine. Each company currently developing a COVID-19 vaccine is taking a slightly different approach, and it’s expected that not every vaccine will successfully get approval for use.
The more approved vaccines there are, the faster they can be manufactured and distributed. Additionally, everyone responds a little differently to medical treatments, so having multiple options of vaccines means people will have more options to get successfully immunized.